Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
| ▸ | RBP4 | P02753 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | BCR | P11274 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13438736 | 0.85 | HPGD (0.54) | LMNAPOLBHPGDSMN1; SMN2MEN1 | |
| SCHEMBL11480218 | 0.85 | HPGD (1.00) | LMNAPOLBHPGDHSD11B1RBP4 | |
| SCHEMBL8104004 | 0.85 | POLB (0.68) | LMNAPOLBHPGDHSD11B1RBP4 | |
| SCHEMBL1534297 | 0.84 | HIF1A (0.58) | LMNAPOLBHPGDMEN1KMT2A | |
| SCHEMBL7581128 | 0.82 | POLB (0.74) | LMNAPOLBHPGDHSD11B1RBP4 | |
| SCHEMBL13503960 | 0.82 | POLB (0.74) | LMNAPOLBHPGDHSD11B1RBP4 | |
| SCHEMBL14223339 | 0.82 | POLB (0.74) | LMNAPOLBHPGDHSD11B1RBP4 | |
| SCHEMBL3124387 | 0.81 | MEN1 (0.71) | HPGDHSD11B1MEN1KMT2AMGLL | |
| Piperazine SCHEMBL28114508 | 0.81 | POLB (0.72) | LMNAPOLBHPGDHSD11B1RBP4 | |
| SCHEMBL28704780 | 0.80 | POLB (0.70) | LMNAPOLBHPGDHSD11B1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | LMNA 2476/4885POLB 4624/4885HPGD 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.